Analyst Ratings for CRISPR Therapeutics (crsp)
crsp Rating Summary
crsp Price Target Summary
- Highest: $268.00 (Brookline Capital Markets)
- Lowest: $6.00 (Baird)
- Average: $79.38
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$79.38 (+48.2%)
* Over Last 12-Mos
Rating Score: 5.6 / 10
Percentile Rank: 59%
Avg. $ Target:
$79.38 (+48.2%)
* Over Last 12-Mos
Rating Score: 5.6 / 10
Percentile Rank: 59%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/11/2026 | Morgan Stanley | Maxwell Skor | New Coverage | Equalweight (N/A) |
60.00 (N/A) |
51.48 (53.55) |
4.02% | Details |
| 9/18/2025 | JPMorgan | Brian Cheng | New Coverage | Overweight (N/A) |
70.00 (N/A) |
61.19 (53.55) |
-12.49% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
